Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Serena-backed health tech lands first FDA approval for home cervical cancer test

From TechCrunch

By Dominic-Madori Davis

May 9, 2025

Serena-backed health tech lands first FDA approval for home cervical cancer test

Serena-backed health tech lands first FDA approval for home cervical cancer test

For the first time, the FDA has just approved a device that lets people screen for cervical cancer from home.

Known as the Teal Wand, from the company Teal Health, the prescription device lets patients self-collect samples and mail them to a lab to receive the same testing as would be done at a doctor’s office. 

Teal Health announced a $10 million seed extensio round in January, bringing its total funding amount to $23 million, TechCrunch covered at the time. Investors in the round included Serena Ventures, Chelsea Clinton, Emerson Collective, and Forerunner. The device seeks to tap into the fact that getting screened for cervical cancer, also known as getting a pap smear, can be quite intimidating for many people. 

“Cervical cancer screenings are the most important and often the entry point to a woman’s health relationship,” Kara Egan, co-founder and CEO, told TechCrunch in January. “More than 1 in 4 women are currently behind on this life-saving screening.”

Cervical cancer used to be one of the most common cancers for women, but more screening and prevention have helped decrease this, per the American Cancer Society. The Wand Kit will include the collection device and virtual access to medical providers who will review the lab results with the patient. Kits become available in June, starting in California.

View original article on techcrunch.com

Most Recent

Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation

Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation

The de-extinction startup is looking to double or triple its previous valuation, according to the report.

Jul 20, 2026

Natural raises $30M to reinvent payments for AI agents — and take on Stripe

Natural raises $30M to reinvent payments for AI agents — and take on Stripe

The one-year-old startup aims to reinvent financial architecture for autonomous AI transactions.

Jul 20, 2026

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

AI infrastructure company Infinity announced Monday a $15 million raise at a $100 million valuation from investors including Touring Capital, Principal VC, and researchers from companies such as OpenAI and Anthropic.

Jul 20, 2026

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

For the first time since 2024, StrictlyVC is coming back to New York City — and we're bringing the kind of access you’d expect from an under-wraps event to the whole startup, VC, and dealmaking community.

Jul 20, 2026

Similar Posts

Sam Altman’s World unveils a mobile verification device

Sam Altman’s World unveils a mobile verification device

Tools for Humanity, the startup behind the World human verification project, unveiled a mobile verification device and expanded to the US.

Apr 30, 2025

Prickly Pear Health will showcase how it’s helping women’s brain health at TechCrunch Disrupt 2025

Prickly Pear Health will showcase how it’s helping women’s brain health at TechCrunch Disrupt 2025

Prickly Pear Health provides medical support for women’s brain health, a voice-first, AI-powered companion that helps women in their 30s to 50s navigate the hormonal changes that affect brain health.

Oct 1, 2025

Healx, an AI-enabled drug discovery platform for rare diseases, raises $47M

Healx, an AI-enabled drug discovery platform for rare diseases, raises $47M

The company also said it has received regulatory clearance to start Phase 2nclinical trials for a new drug in the U.S. later this year.

Aug 1, 2024

Herself Health, providing primary care to women 65 and over, raises $26M

Herself Health, providing primary care to women 65 and over, raises $26M

Six months after raising a $7 million seed round, Herself Health is back with some additional venture capital to expand its clinic footprint.

Jul 17, 2023

Most Recent

Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation

Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation

The de-extinction startup is looking to double or triple its previous valuation, according to the report.

Jul 20, 2026

Natural raises $30M to reinvent payments for AI agents — and take on Stripe

Natural raises $30M to reinvent payments for AI agents — and take on Stripe

The one-year-old startup aims to reinvent financial architecture for autonomous AI transactions.

Jul 20, 2026

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

AI infrastructure company Infinity announced Monday a $15 million raise at a $100 million valuation from investors including Touring Capital, Principal VC, and researchers from companies such as OpenAI and Anthropic.

Jul 20, 2026

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

For the first time since 2024, StrictlyVC is coming back to New York City — and we're bringing the kind of access you’d expect from an under-wraps event to the whole startup, VC, and dealmaking community.

Jul 20, 2026

Similar Posts

Sam Altman’s World unveils a mobile verification device

Sam Altman’s World unveils a mobile verification device

Tools for Humanity, the startup behind the World human verification project, unveiled a mobile verification device and expanded to the US.

Apr 30, 2025

Prickly Pear Health will showcase how it’s helping women’s brain health at TechCrunch Disrupt 2025

Prickly Pear Health will showcase how it’s helping women’s brain health at TechCrunch Disrupt 2025

Prickly Pear Health provides medical support for women’s brain health, a voice-first, AI-powered companion that helps women in their 30s to 50s navigate the hormonal changes that affect brain health.

Oct 1, 2025

Healx, an AI-enabled drug discovery platform for rare diseases, raises $47M

Healx, an AI-enabled drug discovery platform for rare diseases, raises $47M

The company also said it has received regulatory clearance to start Phase 2nclinical trials for a new drug in the U.S. later this year.

Aug 1, 2024

Herself Health, providing primary care to women 65 and over, raises $26M

Herself Health, providing primary care to women 65 and over, raises $26M

Six months after raising a $7 million seed round, Herself Health is back with some additional venture capital to expand its clinic footprint.

Jul 17, 2023